MarketCapExport financials
Voyager Therapeutics (VYGR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Voyager Therapeutics Income Statement 2025-2011 | VYGR
Brief overview of income trends at Voyager Therapeutics
The comparison covers a five-year financial horizon. The revenue attributed to Voyager Therapeutics moved from $171 million to $40.4 million between the two endpoints. Across the full period, sales moved by −76.4%; the average annual rate was −25.1%. The business finished the period with a smaller revenue base.
The five-year EBITDA result moved by −509.6%: from $31.2 million to −$128 million. Operating performance weakened relative to revenue. At the operating-margin level, the figure shifted from 18.2% to −316.5%. The business retained less EBITDA from each unit of revenue.
The final result was 36.7 million dollars initially and −120 million dollars in the final year. Profit turned into a loss, the most concerning signal in the results.
The market value of the business moved from $280 million to $241 million, or −14%. The market value rose well beyond the pace of financial improvement.
Conclusion
The indicators point to a weaker financial profile. The most visible risks are a narrow EBITDA buffer, lower net income and weak sales momentum. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Voyager Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
241 M | 237 M | 386 M | 282 M | 108 M | 280 M | 397 M | 337 M | 571 M | 295 M | 266 M | - | - | - | - |
Shares |
58.7 M | 57.7 M | 43 M | 38.4 M | 37.7 M | 37.1 M | 35.9 M | 32.1 M | 26.8 M | 25.3 M | 24.9 M | - | - | - | - |
Historical Prices |
4.11 | 4.11 | 8.98 | 7.36 | 2.86 | 7.55 | 11 | 10.5 | 20.6 | 11.9 | 10.7 | - | - | - | - |
Net Income |
-120 M | -65 M | 132 M | -46.4 M | -71.2 M | 36.7 M | -43.6 M | -88.3 M | -70.7 M | -40.2 M | -29.7 M | -16.3 M | - | - | - |
Revenue |
40.4 M | 80 M | 250 M | 40.9 M | 37.4 M | 171 M | 104 M | 7.62 M | 10.1 M | 14.2 M | 17.3 M | - | - | - | - |
Operating Income |
-132 M | -83.3 M | 122 M | -50.8 M | -73.6 M | 27.4 M | -51.7 M | -91.1 M | -71.9 M | -41.3 M | -20.3 M | -14.4 M | - | - | - |
Interest Expense |
1.65 M | 622 K | 3 K | 2.65 M | 2.81 M | 7.7 M | 1.62 M | -683 K | -62 K | 182 K | -9.75 M | -1.95 M | - | - | - |
EBITDA |
-128 M | -78.6 M | 126 M | -44.6 M | -68.5 M | 31.2 M | -48.9 M | -89 M | -70.3 M | -40.7 M | -19.7 M | -14.2 M | - | - | - |
Operating Expenses |
172 M | 163 M | 128 M | 91.7 M | 111 M | 144 M | 156 M | 98.7 M | 82 M | 55.5 M | 37.6 M | - | - | - | - |
General and Administrative Expenses |
37.5 M | 35.9 M | 35.8 M | 31 M | 37.2 M | 35 M | 36.3 M | 33.8 M | 19.7 M | 13.3 M | 9.91 M | 5.47 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Voyager Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
61.8 M | 60.5 M | 59.5 M | 83.1 K | 58.8 M | 58.7 M | 58.3 M | 103 K | 57.9 M | 57.7 M | 57.1 M | 2.06 M | 43.9 M | 43.5 M | 40.6 M | 64.3 M | 38.5 M | 38.3 M | 38 M | 45.6 M | 37.8 M | 37.6 M | 37.5 M | 53.2 M | 37.2 M | 37 M | 37 M | 317 K | 36.7 M | 36.6 M | 33.4 M | 88.1 K | 32.2 M | 32 M | 31.8 M | 835 K | 26.2 M | 25.9 M | 25.8 M | 75.4 K | 25.4 M | 25.2 M | 25.1 M | 3.03 M | 1.32 M | 1.14 M | 1 M | 815 K | 684 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-24.7 M | -24.5 M | -27.9 M | -27.4 M | -27.9 M | -33.4 M | -31 M | -34.5 M | -9.04 M | -10.1 M | -11.3 M | 56.4 M | -25.9 M | -22.2 M | 124 M | -23.6 M | 17.6 M | -19.1 M | -21.3 M | 5.71 M | -25.1 M | -30.1 M | -21.6 M | -15.9 M | 85.6 M | -8.68 M | -24.3 M | -12.6 M | -15 M | 11.2 M | -27.2 M | -22.5 M | -20.3 M | -25.5 M | -19.9 M | -11.8 M | -23.3 M | -18.9 M | -16.6 M | -14.7 M | -9 M | -9.34 M | -7.19 M | -8.82 M | -6.91 M | -3.9 M | -14.6 M | -5.2 M | -4 M | -4.86 M | -3.21 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
4.01 M | 3.16 M | 2.59 M | 15.3 M | 13.4 M | 5.2 M | 6.47 M | 6.28 M | 24.6 M | 29.6 M | 19.5 M | 90.1 M | 4.61 M | 4.85 M | 150 M | -1.55 M | 41.1 M | 712 K | 658 K | 28.1 M | 1.48 M | 1.36 M | 6.5 M | 6.54 M | 118 M | 28.7 M | 18.1 M | 32.7 M | 20.4 M | 46.1 M | 5.2 M | 2.01 M | 2.09 M | 2.58 M | 942 K | 6.35 M | 1.15 M | 1.18 M | 1.46 M | 2.36 M | 3.31 M | 3.72 M | 4.83 M | 4.94 M | 4.94 M | 4.88 M | 2.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-26.4 M | -26.4 M | -30.3 M | -29.9 M | -30.6 M | -36.6 M | -34.7 M | -38.3 M | -13.8 M | -15 M | -16.2 M | 54.1 M | -29.5 M | -25.4 M | 123 M | -24.6 M | 14.4 M | -19.4 M | -21.4 M | 5.7 M | -25.1 M | -28.6 M | -25.6 M | -23.7 M | 84.5 M | -8.98 M | -24.4 M | -13.8 M | -17.8 M | 9.19 M | -29.3 M | -23.2 M | -21.1 M | -25.7 M | -21.1 M | -12.3 M | -23.4 M | -18.6 M | -17.5 M | -13.8 M | -10.4 M | -9.62 M | -7.47 M | -7.44 M | -4.02 M | -3.97 M | -4.83 M | -4.5 M | -3.66 M | -3.23 M | -2.98 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
406 K | 411 K | 435 K | 404 K | 400 K | 427 K | 418 K | 402 K | 200 K | 20 K | - | - | - | 3 K | - | -23 K | 2.64 M | 61 K | - | 650 K | -112 K | -1.58 M | 3.92 M | 7.72 M | 830 K | -46 K | -808 K | -198 K | 978 K | -133 K | 978 K | -281 K | -84 K | -717 K | 399 K | 122 K | -282 K | -297 K | 395 K | 617 K | -99 K | -150 K | -186 K | - | -9.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-26.4 M | -25.5 M | -29.3 M | -28.9 M | -29.7 M | -35.6 M | -33.7 M | -37.3 M | -12.6 M | -13.6 M | -15 M | 55.4 M | -28.6 M | -24.3 M | 124 M | -23.7 M | 15.8 M | -18.2 M | -18.5 M | 7.18 M | -23.9 M | -27.4 M | -24.3 M | -22.7 M | 85.6 M | -8.06 M | -23.6 M | -13 M | -17.1 M | 9.86 M | -28.7 M | -22.6 M | -20.6 M | -25.2 M | -20.6 M | -11.9 M | -22.9 M | -18.2 M | -17.2 M | -13.7 M | -10.2 M | -9.47 M | -7.33 M | -7.28 M | -3.96 M | -3.69 M | -4.7 M | -4.5 M | -3.5 M | -3.23 M | -2.98 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
30.4 M | 29.6 M | 32.9 M | 45.3 M | 44 M | 41.8 M | 41.2 M | 44.6 M | 38.4 M | 44.6 M | 35.7 M | 36 M | 34.1 M | 30.3 M | 27.6 M | 23 M | 26.6 M | 20.1 M | 22 M | 22.4 M | 26.6 M | 29.9 M | 32.1 M | 30.3 M | 33.3 M | 37.7 M | 42.5 M | 46.4 M | 38.2 M | 36.9 M | 34.5 M | 25.2 M | 23.2 M | 28.3 M | 22 M | 18.7 M | 24.5 M | 19.8 M | 19 M | 16.2 M | 13.7 M | 13.3 M | 12.3 M | 12.4 M | 8.96 M | 8.85 M | 7.4 M | 4.5 M | 3.66 M | 3.23 M | 2.98 M | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
6.06 M | 7.52 M | 8.26 M | 9.32 M | 8.09 M | 10.5 M | 9.64 M | 8.99 M | 8.17 M | 10.2 M | 8.61 M | 10.2 M | 8.26 M | 8.29 M | 9.03 M | 8.46 M | 7.31 M | 7.55 M | 7.66 M | 8.35 M | 8.71 M | 10.4 M | 9.74 M | 8.27 M | 8.28 M | 8.24 M | 10.2 M | 9.89 M | 8.46 M | 8.32 M | 9.66 M | 8.26 M | 6.61 M | 11.8 M | 7.18 M | 5.37 M | 4.94 M | 4.52 M | 4.91 M | 3.48 M | 3.37 M | 2.85 M | 3.56 M | 3.16 M | 2.48 M | 2.4 M | 1.88 M | - | 1.26 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Voyager Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M |  USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
- | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
- | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
$ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
$ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
$ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
$ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
$ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
$ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
$ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
$ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
$ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
$ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
$ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
$ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
$ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
$ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
$ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
$ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | USA |
 |
Codexis
CDXS
|
$ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
$ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
$ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
$ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
$ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
- | - | - |  Russia |
 |
CorMedix
CRMD
|
$ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
$ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
$ 50.09 | 3.15 % | $ 4.5 B | Schweiz |